Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 249Rectal Neoplasms 154Pancreatic Neoplasms 125Stomach Neoplasms 105Colonic Neoplasms 104Esophageal Neoplasms 90Neoplasm Metastasis 69Breast Neoplasms 61Squamous Cell Carcinoma of Head and Neck 47Carcinoma, Hepatocellular 42Adenocarcinoma Of Esophagus 41Head and Neck Neoplasms 39Esophageal Squamous Cell Carcinoma 38Neoplasms 37Nasopharyngeal Carcinoma 30Adenocarcinoma 24Cholangiocarcinoma 20Keratosis, Actinic 17Carcinoma, Squamous Cell 16Biliary Tract Neoplasms 16Liver Neoplasms 15Gastrointestinal Neoplasms 15Anus Neoplasms 14Gallbladder Neoplasms 11Bile Duct Neoplasms 11Peritoneal Neoplasms 10Laryngeal Neoplasms 9Recurrence 8Nasopharyngeal Neoplasms 7Colorectal Cancer Metastatic 7

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophagogastric Cancer × Fluorouracil × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡